Dermorphin
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, YdAFGYPS-NH2, frog opioid heptapeptide
Dermorphin is an opioid heptapeptide isolated from the skin of South American Phyllomedusa tree frogs. It is a highly potent and highly selective mu-opioid receptor agonist, and it is not a cosmetic or dermatological compound in any sense. It appears in peptide catalogues because it is sold grey-market, and it is best known publicly as a horse-racing doping agent.
Mechanism
Dermorphin is a full agonist at the mu-opioid receptor (MOR, OPRM1), a class A G protein-coupled receptor. Agonist binding activates Gi/Go, which inhibits adenylyl cyclase and lowers cyclic AMP, opens G protein-coupled inwardly rectifying potassium channels to hyperpolarise the neuron, and closes voltage-gated calcium channels to suppress neurotransmitter release from presynaptic terminals. In pain-processing circuits from the dorsal horn to the periaqueductal grey this produces profound analgesia; in the brainstem respiratory centres mu agonism produces respiratory depression; in the ventral tegmental area it produces euphoria and reinforcement. This is the same receptor and the same signalling cascade as morphine and fentanyl.
How much more potent than morphine dermorphin is depends entirely on the assay, and the commonly quoted single figure is misleading. Broccardo and colleagues (1981) found it roughly 39 times more potent than morphine on guinea-pig ileum opiate receptors and about 40 times more potent on the vas deferens, the origin of the '30 to 40 times more potent' figure that Guan and colleagues also quote. But in analgesia testing after intracerebroventricular administration in rats, morphine was 752 to 2,170 times less potent depending on the test used. Isolated-tissue ratios and central analgesic ratios are not interchangeable.
Two structural features make dermorphin remarkable. The first is its mu selectivity, which is far cleaner than morphine's. The second is the D-alanine at position 2. Vertebrate peptides are built from L-amino acids; the D-residue in dermorphin was, on its 1981 discovery, unprecedented in a vertebrate peptide. Broccardo's group showed that the D-Ala2 residue was of crucial importance to activity, and that the N-terminal tetrapeptide was the minimum sequence for full activity. Practically, the D-residue blocks aminopeptidase cleavage of the Tyr-Ala bond, which is the principal route by which endogenous enkephalins are destroyed within seconds. That is why dermorphin is durable enough to be pharmacologically useful.
What the research shows
Montecucchi and colleagues isolated and sequenced dermorphin in 1981 from methanol extracts of Phyllomedusa sauvagei skin, establishing both the heptapeptide sequence and the presence of a D-amino acid in a vertebrate peptide. Broccardo and colleagues characterised the pharmacology in the same year, confirming extreme mu-opioid potency in animal models, showing that naloxone antagonised it powerfully in both preparations, and (a point rarely repeated) finding that tolerance and physical dependence developed consistently less markedly with dermorphin than with morphine.
Only one prospective randomised double-blind human clinical trial of dermorphin has ever been published. Basso and colleagues (1985) compared intrathecal dermorphin 20 micrograms, intrathecal morphine 500 micrograms and routine intramuscular pentazocine 30 mg in 150 consecutive patients after elective surgery. Mean duration of analgesia was 43.41 hours with dermorphin, 34.45 hours with intrathecal morphine and 10.79 hours with pentazocine. Mean postoperative hospital stay was significantly shorter in both intrathecal groups than in the control group. Side effects that the paper enumerates (urinary retention, vomiting and headache) were not significantly different between the three groups. Reporting doses used in a published trial is a matter of record; it is not guidance, and dermorphin is not a medicine anyone can lawfully be given. It is worth being clear about the limits of this paper: it is three pages in a conference supplement, and it does not report respiratory monitoring, rescue-analgesia rates, or the surgical case-mix in any detail. Claims circulating online that it demonstrated an absence of respiratory depression, or gave specific rescue-analgesia percentages, are not supported by the published report.
Keppel Hesselink and Schatman (2018) and Liebregts and colleagues (2019) have both argued for revisiting the compound. The 2018 paper documents something striking: the 1985 trial was essentially never cited by clinicians, with only around fifteen pharmacological and review papers mentioning it afterwards and not one clinical paper, and interest in the compound simply evaporated after 1985. These are advocacy commentaries, not new evidence. One 1985 supplement paper, by modern standards, is a signal and not a conclusion.
The compound resurfaced publicly in 2011 when intelligence from North American racetracks indicated it was being administered to racehorses to mask pain, undetected because no assay existed. Guan and colleagues (2013) developed the first LC-MS/MS method for detecting and quantifying dermorphin in equine plasma and urine, with limits of detection of 10 pg/mL in plasma and 20 pg/mL in urine, limits of confirmation of 20 and 50 pg/mL, and the ability to distinguish dermorphin from its diastereomer. Regulatory action followed. There is no human medical use anywhere in the world.
Evidence assessment
Limited evidence
A single randomised double-blind human trial from 1985, published as a three-page conference supplement article, reported strongly positive results in postoperative analgesia and has never been replicated in the four decades since; everything else in humans is absent.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei Preclinical only
Established the sequence H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 and identified the first D-amino acid residue found in a vertebrate peptide.
Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin Preclinical only
Dermorphin was about 39 times more potent than morphine on guinea-pig ileum and about 40 times more potent on vas deferens, but 752 to 2,170 times more potent than morphine in analgesia after intracerebroventricular administration in rats. Naloxone antagonised it powerfully. Tolerance and physical dependence developed consistently less markedly than with morphine. The N-terminal tetrapeptide was the minimum sequence for full activity, with the D-Ala2 residue of crucial importance.
Intrathecal dermorphine in postoperative analgesia Limited evidence
Mean analgesia duration 43.41 hours with dermorphin versus 34.45 hours with intrathecal morphine and 10.79 hours with pentazocine; postoperative hospital stay was significantly shorter in both intrathecal groups than in the control group; side effects (urinary retention, vomiting, headache) did not differ significantly between the three groups.
Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation Limited evidence
Documents that the 1985 clinical trial was essentially never cited by clinicians (only around fifteen pharmacological and review papers mentioned it afterwards, none of them clinical) and argues for new studies of intrathecal dermorphin in postoperative and palliative pain.
Dermorphin: A Missed Palliative Care Opportunity for Intrathecal Therapy in Oncological Patients? Limited evidence
Argues that dermorphin represents a missed opportunity for intrathecal therapy in oncological palliative care and calls for renewed investigation.
Detection, quantification, and identification of dermorphin in equine plasma and urine by LC-MS/MS for doping control Preclinical only
Established the first LC-MS/MS assay for dermorphin in equine samples, with limits of detection of 10 pg/mL in plasma and 20 pg/mL in urine, limits of confirmation of 20 and 50 pg/mL, and the ability to distinguish dermorphin from its diastereomer.
Safety
Dermorphin is a potent mu-opioid full agonist and carries the full opioid risk profile: dose-dependent respiratory depression, sedation, nausea and vomiting, urinary retention, constipation, tolerance, physical dependence and addiction. Its potency relative to morphine means the margin between an analgesic and a respiratory-arrest dose is correspondingly narrow, and its resistance to enzymatic degradation prolongs any overdose. The 1985 trial reported that urinary retention, vomiting and headache did not differ significantly between the three arms; it does not report on respiratory depression at all, and its silence on that point is a limitation of a three-page paper, not evidence of safety.
The limits of the safety record are severe. There has been essentially no human exposure since 1985 and no modern pharmacovigilance whatsoever. Nothing is known about chronic use, drug interactions, overdose management or reversal characteristics beyond the animal finding that naloxone is a powerful antagonist. Material sold online under 'for research use only' labelling is unregulated and of unverified identity and purity, and is being sold to consumers for self-administration of an opioid many times more potent than morphine, that phrase functioning as a legal shield rather than a description of intended use. There is no legitimate route by which a member of the public should be handling this compound.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation; supply for human use would fall under the Human Medicines Regulations 2012 as an unlicensed medicinal product. It is not listed by name in the Misuse of Drugs Act 1971 schedules, but as a psychoactive opioid it falls within the scope of the Psychoactive Substances Act 2016, under which production, supply and import for human consumption are offences. Prohibited under British Horseracing Authority anti-doping rules. |
| United States | No FDA approval for any indication and no marketing authorisation anywhere in the world. It is an unapproved new drug; distribution for human use is unlawful under the Federal Food, Drug, and Cosmetic Act. It is not scheduled by name under the Controlled Substances Act. Claims that it falls under the federal Analogue Act are doubtful: the Analogue Act requires a chemical structure substantially similar to a Schedule I or II substance, and a heptapeptide is not structurally similar to morphine or fentanyl despite acting at the same receptor. Its administration to racehorses is prohibited under the rules of United States racing authorities and has drawn regulatory sanction against trainers and veterinarians. |
| WADA (sport) | Prohibited. Dermorphin is not named in the closed S7 Narcotics list, but it is captured by S0 (Non-Approved Substances), which prohibits at all times any pharmacological substance not addressed elsewhere on the List and holding no current approval by any governmental regulatory health authority for human therapeutic use. |
Questions
No. Despite the name, dermorphin has nothing to do with dermatology: 'derm' refers to the frog skin it was isolated from, not to human skin. It is a mu-opioid receptor agonist with no cosmetic, dermatological or anti-ageing application whatsoever. It appears in peptide catalogues only because it is sold on the grey market.
It depends entirely on the assay, which is why the commonly quoted single number is misleading. In isolated tissue preparations the 1981 pharmacology paper found it about 39 to 40 times more potent than morphine, the origin of the '30 to 40 times' figure. But for analgesia after direct administration into the brain in rats, morphine was 752 to 2,170 times less potent. Both figures are from the same paper.
From around 2011, intelligence from North American racetracks indicated dermorphin was being given to racehorses to mask pain, and it was going undetected because no assay existed for it. A validated LC-MS/MS detection method was published in 2013, positive tests followed, and regulatory action against trainers and veterinarians ensued. It is banned by every major racing authority.
The 'for research use only' label on vials sold online is a legal shield allowing unapproved compounds to be sold to consumers; it is not a statement about safety, purity or lawful human use. Dermorphin has no marketing authorisation anywhere. In the UK, supplying a psychoactive opioid for human consumption is an offence under the Psychoactive Substances Act 2016. In the US it is an unapproved new drug, though the often-repeated claim that it falls under the Analogue Act is doubtful given its peptide structure.